Business Context and Reporting Period
Company: Akari Therapeutics Plc
Filing Type: Form 8-K (Current Report)
Date of Report: October 14, 2025
Event: Entry into a Material Definitive Agreement for a registered direct offering of securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Securities Issued: 3,125,000 American Depositary Shares (ADSs), each representing 2,000 ordinary shares.
- Warrants Issued: Series E and Series F warrants to purchase up to 3,125,000 ADSs each.
- Purchase Price: $0.80 per ADS (combined with accompanying Warrants).
- Gross Proceeds: Approximately $2.5 million (excluding future warrant exercises).
- Use of Proceeds: Working capital, general corporate purposes, and research and development (R&D), specifically for generating data on a novel ADC payload.
- Transaction Costs: Placement agent fee of 7.2% of gross proceeds, management fee of 0.5%, and a non-accountable expense allowance up to $75,000.
Material Changes and Transaction Structure
The filing reports the execution of a Securities Purchase Agreement with institutional investors. Material terms include:
- Warrant Terms:
- Series E Warrants: Exercise price of $0.98 per share; 5-year term; exercisable upon shareholder approval.
- Series F Warrants: Exercise price of $0.98 per share; 30-month term; exercisable upon shareholder approval.
- Placement Agent Warrants: 125,000 ADSs (4.0% of offering); exercise price of $1.00 per share; 5-year term.
- Shareholder Approval: Required for warrant exercise. A special meeting must be called within 60 days of the closing date. If not obtained, meetings will be called every 40 days thereafter.
- Lock-Up Provisions: The Company is restricted from issuing additional equity or filing registration statements for 30 days post-closing. A one-year restriction on "variable rate transactions" also applies.
- Ownership Limitations: Warrant holders cannot exercise if it would result in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding ordinary shares.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use proceeds to advance R&D, specifically to generate differentiated data on a novel ADC payload to be presented at the Society for Immunotherapy Cancer Society Annual Meeting in early November 2025.
Risks and Contingencies:
- Closing Conditions: The offering is expected to close on or about October 16, 2025, subject to customary closing conditions. Failure to satisfy these conditions may prevent the closing.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the closing date and use of proceeds, which are not guaranteed.
- Registration Status: Warrants and underlying shares are sold pursuant to exemptions from registration and may not be resold in the U.S. without an effective registration statement or applicable exemption.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected October 16, 2025) and confirmation of gross proceeds received.
- Monitor the scheduling and outcome of the Special Meeting of Shareholders required to approve the warrant exercises.
- Review the upcoming presentation at the Society for Immunotherapy Cancer Society Annual Meeting for data on the novel ADC payload.
- Confirm the filing of the registration statement for the resale of ADSs underlying the warrants within 30 days of the closing date.
- Assess the impact of the 7.7% total fees (7.2% placement + 0.5% management) on the net capital raised.